Neuland Laboratories Ltd. News and Updates

Name: Latest research reports of Neuland Laboratories Ltd. authored by BP Wealth and published by - Trendlyne research reports.
Item: Neuland Laboratories Ltd.
Rating: 3
Author: BP Wealth

Keep track of all breaking news on Neuland Laboratories Ltd. from all sources in a single place.

Load latest

Neuland Laboratories Ltd.

13 May 2021

13801.00

0.61%

BP Equities Neuland Lab Ltd Q4FY21 Result Update

Hold: Neuland Laboratories Ltd.

Target

BP Wealth

growth in profitability, healthy balance sheet with improving return ratios, we continue to remain Face Value (INR) optimistic about the mid to long-term growth prospects of the company. The stock has experienced a Average volume significant re-rating in the recent past as the company has been consistently delivering strong growth 3 months along with margin expansion. We foresee a 16.7% revenue CAGR, 277bps margin increase over 6 months FY21-23E. The balance of portfolio among high value and high volume products will help it clock a 1 year faster growth in earnings. Considering better growth visibility, we raised our earnings estimate for...

Neuland Laboratories Ltd. is trading above all available SMAs

Neuland Laboratories Ltd.

11 May 2021

13801.00

0.61%

Neuland Lab Consolidated March 2021 Net Sales at Rs 244.70 crore, up 27.69% Y-o-Y

Moneycontrol

NULL

Number of FII/FPI investors increased from 250 to 259 in Jun 2025 qtr.

Neuland Laboratories Ltd.

03 Feb 2021

13801.00

0.61%

BP Equities Neuland Lab Ltd Q3FY21 Result Update

Hold: Neuland Laboratories Ltd.

Target

BP Wealth

Neuland lab (NLL) has posted revenue of INR 2,454mn with a 20.4% YoY increase, which was 14% above our estimate of INR 2,150mn. The revenue growth was mainly driven by strong traction in the CMS (78.6% YoY growth) segment, led by 33 molecules (Development + Commercialize) along with the Speciality API segment, which grew by 20.5% in Q3FY21. EBITDA margin expanded by 510bps to 19% level, which was 76bps higher than our estimate driven by improved product mix. Management is confident to improve margin profile from the current level on the back of strong order book in CMS business, better traction in GDS business, and cost optimization measures. NLL reported a PAT of INR 267mn (up 141% YoY) compared to our PAT estimate of INR 202mn led by operationally...

Number of FII/FPI investors increased from 250 to 259 in Jun 2025 qtr.

Neuland Laboratories Ltd.

02 Feb 2021

13801.00

0.61%

Neuland Lab Consolidated December 2020 Net Sales at Rs 245.39 crore, up 20.38% Y-o-Y

Moneycontrol

NULL

Neuland Laboratories Ltd. has gained 71.35% in the last 1 Year

Neuland Laboratories Ltd.

04 Nov 2020

13801.00

0.61%

BP Equities Neuland Lab Ltd Q2FY21 Result Update

Hold: Neuland Laboratories Ltd.

Recommendation Target

BP Wealth

Neuland lab (NLL) has posted revenue of INR2,414mn with a 29.6% YoY increase, which was 12% below our estimate of INR 2,160mn. The revenue growth was mainly driven by strong traction in the CMS (54.6% YoY growth) segment, led by 33 molecules (Development + Commercialize) along with...

Neuland Laboratories Ltd. has gained 71.35% in the last 1 Year

Neuland Laboratories Ltd.

03 Nov 2020

13801.00

0.61%

Neuland Laboratories nets 21 crore in Q2

Business Line

Income up at 242 crore

Neuland Laboratories Ltd. is trading above all available SMAs

Neuland Laboratories Ltd.

05 Aug 2020

13801.00

0.61%

Neuland Lab Consolidated June 2020 Net Sales at Rs 205.42 crore, up 13.49% Y-o-Y

Moneycontrol

NULL

Number of FII/FPI investors increased from 250 to 259 in Jun 2025 qtr.

Neuland Laboratories Ltd.

05 Aug 2020

13801.00

0.61%

BP Equities Neuland Lab Ltd Q1FY21 Result Update

Buy: Neuland Laboratories Ltd.

Recommendation Target

BP Wealth

low our estimate of INR 2,149mn. The revenue growth was mainly driven by the CMS (25.4% YoY growth) segment, led by 32 molecules (Development + Commercialize) with speciality API segment, which grew by 33.2% in Q1FY21. EBITDA margin expanded by 622bps to 16.5% level, which was 219bps higher than our estimate driven by 580bps improvement in gross margin led by improved product mix. Management is confident to improve margin profile from current level on the back of strong order book in CMS business, better traction in GDS business and cost optimization measures....

Number of FII/FPI investors increased from 250 to 259 in Jun 2025 qtr.

Neuland Laboratories Ltd.

28 May 2020

13801.00

0.61%

Neuland Lab Standalone March 2020 Net Sales at Rs 191.87 crore, up 11.12% Y-o-Y

Moneycontrol

NULL

Neuland Laboratories Ltd. is trading above all available SMAs

Neuland Laboratories Ltd.

24 May 2020, 12:00AM

13801.00

0.61%

BP Equities Neuland Lab Ltd Q4FY20 Result Update

Sell: Neuland Laboratories Ltd.

Recommendation Target

BP Wealth

below our estimate of INR 2,032mn. The revenue growth was mainly driven by the CMS (62% YoY growth) segment, led by 25 molecules with speciality API segment, which grew by 18.9% in Q4FY20. EBITDA margin expanded by 498bps to 15.6% level, which was 274bps higher than our estimate due...

Number of FII/FPI investors increased from 250 to 259 in Jun 2025 qtr.

Is Neuland Laboratories Ltd. worth buying?

177 Votes:

Buy 77.4%

Sell 14.12%

Hold 8.47%

72.01% Gain from 52W Low

Neuland Laboratories Ltd. News and Updates

Keep track of all breaking news on Neuland Laboratories Ltd. from all sources in a single place.